Rytvela(一种新型变构抗炎治疗药物)的药效学特征:预防早产并改善胎儿及新生儿结局
本研究在脂多糖或白细胞介素1β诱导的早产小鼠模型中评估变构白细胞介素1受体拮抗剂rytvela的最佳剂量与最短疗程。Rytvela在2 mg/kg/d时减少70%脂多糖诱导及早产60%白细胞介素1β诱导的早产,1 mg/kg/d时提高新生儿存活率达65%。治疗36小时可预防早产和胎儿死亡并保护肺肠完整性。
要点
- Rytvela在2 mg/kg/d时减少70%脂多糖诱导和60%白细胞介素1β诱导的早产。
- 1 mg/kg/d时提高两种早产模型的新生儿存活率达65%。
- 治疗36小时可预防早产和胎儿死亡并保护肺肠完整性。
核心结论
- Rytvela在2 mg/kg/d时达到最大疗效,改善出生结局,且仅治疗36小时即可预防炎症上调。
- Rytvela表现出安全预防早产和保护胎儿的理想特性。
研究设计与样本
- 妊娠CD-1小鼠在妊娠第16天接受脂多糖(10 μg,腹腔注射)或白细胞介素1(1 μg/kg,宫内注射)诱导早产。
- Rytvela以不同剂量(0.1、0.5、1.0、2.0、4.0 mg/kg/d,皮下注射)从妊娠第16天至第18.5天给药。
- 评估最短疗程时,小鼠接受rytvela(2 mg/kg/d,皮下注射)治疗24、36或48小时。
- 评估早产率(妊娠第<18.5天)、新生儿存活和体重,并于妊娠第17.5天收集妊娠组织定量细胞因子、促炎介质和子宫激活蛋白。
- 产后第5至7天收集新生儿肺和肠进行组织学分析。
主要发现
- Rytvela呈剂量反应曲线,在2 mg/kg/d时减少70%脂多糖诱导的早产和60%白细胞介素1β诱导的早产。
- Rytvela在1 mg/kg/d时提高两种早产模型的新生儿存活率达65%。
- Rytvela自治疗24小时起保护胎儿免受炎症损伤,维持肺和肠完整性。
- Rytvela自治疗36小时起分别预防60%的早产和50%的胎儿死亡。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preterm birth is the leading cause of neonatal morbidity and mortality. Studies have shown that interleukin 1 plays a major role in the pathophysiology of preterm birth by inducing the production of proinflammatory mediators and uterine activation proteins leading to labor. More importantly, uteroplacental inflammation, associated with preterm birth parturition pathways, is detrimental to fetal tissues and leads to long-term sequelae. Our group has developed an allosteric antagonist of the interleukin 1 receptor, rytvela, found to be potent and safe in preventing preterm birth by suppressing inflammation via the inhibition of the mitogen-activated protein kinase pathway while preserving the Nuclear factor kappa B pathway (important in immune vigilance). Rytvela has been shown to inhibit inflammatory up-regulation and uterine activation while preserving fetal development. OBJECTIVE: This study aimed to further the preclinical development of rytvela by evaluating its optimal dose and minimal duration of treatment to inhibit the inflammatory cascade, prolong gestation, and promote neonatal outcomes. STUDY DESIGN: Pregnant CD-1 mice were administered with lipopolysaccharide (10 μg, intraperitoneal administration) or interleukin 1 (1 μg/kg, intrauterine administration) on gestational day 16 to induce preterm labor. Rytvela was administered at different doses (0.1, 0.5, 1.0, 2.0, 4.0 mg/kg/d subcutaneously) from gestational days 16 to 18.5. To evaluate the minimal duration of treatment, the mice were administered with rytvela (2 mg/kg/d subcutaneously) for 24, 36, or 48 hours. The rate of prematurity (gestational day <18.5) and neonate survival and weight were evaluated. Gestational tissues were collected at gestational day 17.5 to quantify cytokines, proinflammatory mediators, and uterine activating proteins by real-time quantitative polymerase chain reaction and enzyme-linked immunosorbent assay. The neonatal lungs and intestines were collected from postnatal days 5 to 7 and analyzed by histology. RESULTS: Rytvela exhibited a dose-response profile and achieved maximum efficacy at a dose of 2 mg/kg/d by reducing 70% of lipopolysaccharide-induced preterm births and 60% of interleukin 1β-induced preterm births. In addition, rytvela attained maximum efficacy at a dose of 1 mg/kg/d by increasing neonate survival by up to 65% in both models of preterm birth. Rytvela protected fetuses from inflammatory insult as of 24 hours, preserving lung and intestinal integrity, and prevented preterm birth and fetal mortality by 60% and 50%, respectively, as of 36 hours of treatment. CONCLUSION: The maximum efficacy of rytvela was achieved at 2 mg/kg/d with improved birth outcomes and prevented inflammatory up-regulation upon 36 hours (only) of treatment. Rytvela exhibited desirable properties for the safe prevention of preterm birth and fetal protection.
引用
- Habelrih T, Tremblay DÉ, Di Battista E, et al. Pharmacodynamic characterization of rytvela, a novel allosteric anti-inflammatory therapeutic, to prevent preterm birth and improve fetal and neonatal outcomes. Am J Obstet Gynecol. 2022. PMID: 36244408. doi:10.1016/j.ajog.2022.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。